Clinical Trial Update: A Study of TQ-B3525 Tablets in Subjects With PIK3CA and/or PIK3R1/2 Gene-altered Recurrent/Metastatic Advanced Gynecologic Tumors [Phase 2]

View source ↗

Summary

Phase 2 study of TQ-B3525 tablets in gynecologic tumors with PIK3CA/PIK3R1/2 alterations (advanced endometrial, cervical, and ovarian cancers) with unknown stat…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cervical Cancer
• Endometrial Cancer
• Ovarian Cancer

Drugs mentioned

• TQ-B3525

Snippet

Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Conditions: Advanced Endometrial Cancer, Cervical Cancer and Ovarian Cancer | Phase 2 | Status: UNKNOWN